Europe Pharmacovigilance Market (2024 - 2030) Size, Share & Trends Analysis Report By Service Provider, By Product Life Cycle, By Therapeutic Area, By Process Flow, By End-use, By Type, By Country, And Segment Forecasts

Table of Contents

Chapter 1 Executive Summary
                  1.1 Market Snapshot
                  1.2 Segment Snapshot (Product Life Cycle & Service Provider)
                  1.3 Segment Snapshot (Type & Therapeutic Area)
                  1.4 Segment Snapshot (Process Flow & End Use)
                  1.5 Competitive Landscape Snapshot
Chapter 2 Europe Pharmacovigilance Market Variables, Trends, & Scope
                  2.1 Market Lineage Outlook
                  2.2 Europe Pharmacovigilance Market Dynamics
                       2.2.1 Market Driver Analysis
                           2.2.1.1 Growing drug consumption and drug development rates
                           2.2.1.2 Increasing incidence of ADR and drug toxicity
                           2.2.1.3 Increasing trend of outsourcing pharmacovigilance services
                           2.2.1.4 Increasing externalization of clinical trial studies by large pharmaceutical and biopharmaceutical companies
                           2.2.1.5 Increasing Regulatory Burden on Manufacturers
                           2.2.1.6 Introduction of technologically advanced software services
                           2.2.1.7 Constantly rising investment on R&D by healthcare companies
                           2.2.1.8 Partnerships and collaborations between market players
                       2.2.2 Market Restraint Analysis
                           2.2.2.1 Shortage of skilled labor
                           2.2.2.2 Expensive technology for small and mid-sized player
                           2.2.2.3 Lack of recognition
                           2.2.2.4 Scarcity of integration standards
                       2.2.3 Industry Challenges
                  2.3 Europe Pharmacovigilance Market Analysis Tools: Porters
                  2.4 SWOT Analysis, by Factor (political & legal, economic, and technological)
                  2.5 Value Chain Analysis
                       2.5.1 Preclinical
                       2.5.2 Clinical
                       2.5.3 PMA
                  2.6 Mapping of Life Cycle Against Service Offering and Their Demand
                  2.7 Regulatory Framework
                       2.7.1 List Of Regulatory Bodies By Country
                  2.8 Organization Structure Introduction
                  2.9 Pricing Models
                       2.9.1 Drug Safety Budget Allocation By Activities
                       2.9.2 By Development Phase
                       2.9.3 By Therapeutic Area
                       2.9.4 Pricing Level
                           2.9.4.1 Project management
                           2.9.4.2 Case processing
                           2.9.4.3 ADR Reporting
                           2.9.4.4 Medical writing
                  2.10 Technology Timeline Overview
                       2.10.1 Changing Technology & Adoption
                           2.10.1.1 Social Media
                           2.10.1.2 Literature screening
                           2.10.1.3 Automation and AI
                           2.10.1.4 Big data analytics in PV
                  2.11 Impact of COVID-19
                       2.11.1 Recent Developments & Strategic Outcomes
                           2.11.1.1 Regulatory requirements/changes due to covid-19
                           2.11.1.2 Strategies implemented by companies
                                2.11.1.2.1 IQVIA
                                2.11.1.2.2 PAREXEL International Corporation
                                2.11.1.2.3 Bioclinica
                                2.11.1.2.4 Pharmaceutical Product Development (PPD)
                                2.11.1.2.5 IBM Corporation
                                2.11.1.2.6 ICON, plc
                                2.11.1.2.7 PRA Health Sciences
                                2.11.1.2.8 ArisGlobal
                                2.11.1.2.9 Linical Accelovance
                                2.11.1.2.10 Laboratory Corporation of America Holdings
                  2.12 Market Trends
                       2.12.1 Scaling Of Resources
                       2.12.2 Automation In Pharmacovigilance
                  2.13 Impact of Inflation
Chapter 3 Europe Pharmacovigilance Market: Product Life-Cycle Estimates & Trend Analysis
                  3.1 Product Life Cycle Market Share Analysis, 2023 & 2030
                  3.2 Product Life Cycle Dashboard
                  3.3 Market Definition and Scope
                       3.3.1 Preclinical
                           3.3.1.1 Preclinical market estimates and forecasts, 2018 - 2030 (USD Million)
                       3.3.2 PHASE I
                       3.3.3 PHASE II
                       3.3.4 PHASE III
                       3.3.5 PHASE IV
Chapter 4 Europe Pharmacovigilance Market: Service Provider Estimates & Trend Analysis
                  4.1 Service Provider Market Share Analysis, 2023 & 2030
                  4.2 Service Provider Dashboard
                  4.3 Market Definition and Scope
                       4.3.1 IN HOUSE
                           4.3.1.1 In house market estimates and forecasts, 2018 - 2030 (USD Million)
                       4.3.2 Contract Outsourcing
Chapter 5 Europe Pharmacovigilance Market: Type Estimates & Trend Analysis
                  5.1 Type Market Share Analysis, 2023 & 2030
                  5.2 Type Dashboard
                  5.3 Market Definition and Scope
                       5.3.1 Spontaneous Reporting
                           5.3.1.1 Spontaneous Reporting Market Estimates And Forecasts, 2018 - 2030 (USD Million)
                       5.3.2 Intensified ADR Reporting
                       5.3.3 Targeted Spontaneous Reporting
                       5.3.4 Cohort Event Monitoring (CEM)
                       5.3.5 EHR MINING
Chapter 6 Europe Pharmacovigilance Market: Process Flow Estimates & Trend Analysis
                  6.1 Process Flow Market Share Analysis, 2023 & 2030
                  6.2 Process Flow Dashboard
                  6.3 Market Definition and Scope
                       6.3.1 Case Data Management
                           6.3.1.1 Case Data Management Market Estimates And Forecasts, 2018 - 2030 (Usd Million)
                           6.3.1.2 Case Logging
                           6.3.1.3 Case Data Analysis
                           6.3.1.4 Medical Reviewing And Reporting
                       6.3.2 Signal Detection
                           6.3.2.1 Adverse Event Logging
                           6.3.2.2 Adverse Event Analysis
                           6.3.2.3 Adverse Event Review & Reporting
                       6.3.3 Risk Mamangement System
                           6.3.3.1 Risk Evaluation System
                           6.3.3.2 Risk Mitigation System
Chapter 7 Europe Pharmacovigilance Market: Therapeutic Area Estimates & Trend Analysis
                  7.1 Therapeutic Area Market Share Analysis, 2023 & 2030
                  7.2 Therapeutic Area Dashboard
                  7.3 Market Definition and Scope
                       7.3.1 Oncology
                           7.3.1.1 Oncology Market Estimates And Forecasts, 2018 - 2030 (Usd Million)
                       7.3.2 Neurology
                       7.3.3 Cardiology
                       7.3.4 Respiratory Systems
                       7.3.5 Others
Chapter 8 Europe Pharmacovigilance Market: End-Use Estimates & Trend Analysis
                  8.1 End Use Market Share Analysis, 2023 & 2030
                  8.2 End Use Dashboard
                  8.3 Market Definition and Scope
                       8.3.1 Pharmacuticals
                           8.3.1.1 Pharmaceuticals Market Estimates And Forecasts, 2018 - 2030 (Usd Million)
                       8.3.2 Biotechnology Companies
                       8.3.3 Medical Device Manufacturers
                       8.3.4 Others
Chapter 9 Europe Pharmacovigilance Market: Country Estimates & Trend Analysis
                  9.1 Europe
                       9.1.1 Europe Pharmacovigilance Market Estimates And Forecasts, 2018 - 2030 (Usd Million)
                       9.1.2 Uk
                           9.1.1.1 Uk Pharmacovigilance Market Estimates And Forecasts, 2018 - 2030 (USD Million)
                           9.1.1.2 Competitive Scenario
                           9.1.1.3 Regulatory Framework
                       9.1.3 Germany
                           9.1.3.1 Germany Pharmacovigilance Market Estimates And Forecasts, 2018 - 2030 (USD Million)
                           9.1.3.2 Competitive Scenario
                           9.1.3.3 Regulatory Framework
                       9.1.4 France
                           9.1.4.1 France Pharmacovigilance Market Estimates And Forecasts, 2018 - 2030 (USD Million)
                           9.1.4.2 Competitive Scenario
                           9.1.4.3 Regulatory Framework
                       9.1.5 Italy
                           9.1.5.1 Italy Pharmacovigilance Market Estimates And Forecasts, 2018 - 2030 (USD Million)
                           9.1.5.2 Competitive Scenario
                           9.1.5.3 Regulatory Framework
                       9.1.6 Spain
                           9.1.6.1 Spain Pharmacovigilance Market Estimates And Forecasts, 2018 - 2030 (USD Million)
                           9.1.6.2 Competitive Scenario
                           9.1.7.3 Regulatory Framework
                       9.1.7 Russia
                           9.1.7.1 Russia Pharmacovigilance Market Estimates And Forecasts, 2018 - 2030 (USD Million)
                           9.1.7.2 Competitive Scenario
                           9.1.7.3 Regulatory Framework
                       9.1.8 Denmark
                           9.1.8.1 Denmark Pharmacovigilance Market Estimates And Forecasts, 2018 - 2030 (USD Million)
                           9.1.8.2 Competitive Scenario
                           9.1.8.3 Regulatory Framework
                       9.1.9 Norway
                           9.1.9.1 Norway Pharmacovigilance Market Estimates And Forecasts, 2018 - 2030 (USD Million)
                           9.1.9.2 Competitive Scenario
                           9.1.9.3 Regulatory Framework
                       9.1.10 Sweden
                           9.1.10.1 Sweden Pharmacovigilance Market Estimates And Forecasts, 2018 - 2030 (USD Million)
                           9.1.10.2 Competitive Scenario
                           9.1.10.3 Regulatory Framework
Chapter 10 Europe Pharmacovigilance Market: Competitive Analysis
                  10.1 Market Participation Categorization
                  10.2 Public Companies
                       10.2.1 Company Market Position Analysis
                       10.2.2 Company Market Share
                  10.3 Private Companies
                       10.3.1 List Of Key Emerging Companies
                  10.4 Competitive Factors And Strategies
                       10.4.1 Increasing Strategic Collaborations And Product Launches
                       10.4.2 Strategic Government Initiatives Which Include Collaborations
                       10.4.3 Competitors Increased PV Awareness Programs
                       10.4.4 Competitors Increased Collaboration And Outsourcing Of Operations
                       10.4.5 Consolidation Trends
                  10.5 Healthcare Companies Using Pharmacovigilance Services
                       10.5.1 Potential Customers
                       10.5.2 Notable Use Cases
                           10.5.2.1 Case Study 1
                                10.5.2.1.1 Part 1
                                10.5.2.1.2 Part 2
                           10.5.2.2 Case Study 2
                           10.5.2.3 Case Study 3
                           10.5.2.4 Case Study 4
                       10.5.3 Key Focus Areas For The Pharmaceutical/Healthcare Companies
                           10.5.3.1 Adoption Of Technological Advancements In Life Sciences Industry
                           10.5.3.2 Published Survey Insights - Related To Adoption Of Pharmacovigilance Automation
Chapter 11 Competitive Landscape
                  11.1 Company Profiles
                       11.1.1 PAREXEL INTERNATIONAL CORPORATION.
                           11.1.1.1 Company Overview
                           11.1.1.2 Service Benchmarking
                           11.1.1.3 Financial Performance
                           11.1.1.4 Strategic Initiatives
                           11.1.1.5 Swot Analysis
                       11.1.2 ACCENTURE
                           11.1.2.1 Company Overview
                           11.1.2.2 Service Benchmarking
                           11.1.2.3 Financial Performance
                           11.1.2.4 Strategic Initiatives
                           11.1.2.5 Swot Analysis
                       11.1.3 CLINQUEST GROUP B.V. (LINICAL AMERICAS)
                           11.1.3.1 Company Overview
                           11.1.3.2 Service Benchmarking
                           11.1.3.3 Financial Performance
                           11.1.3.4 Strategic Initiatives
                           11.1.3.5 Swot Analysis
                       11.1.4 IQVIA
                           11.1.4.1 Company Overview
                           11.1.4.2 Service Benchmarking
                           11.1.4.3 Financial Performance
                           11.1.4.4 Strategic Initiatives
                           11.1.4.5 Swot Analysis
                       11.1.5 COGNIZANT
                           11.1.5.1 Company Overview
                           11.1.5.2 Service Benchmarking
                           11.1.5.3 Financial Performance
                           11.1.5.4 Strategic Initiatives
                           11.1.5.5 Swot Analysis
                       11.1.6 LABORATORY CORPORATION OF AMERICA HOLDINGS
                           11.1.6.1 Company Overview
                           11.1.6.2 Service Benchmarking
                           11.1.6.3 Financial Performance
                           11.1.6.4 Strategic Initiatives
                           11.1.6.5 Swot Analysis
                       11.1.7 IBM CORPORATION
                           11.1.7.1 Company Overview
                           11.1.7.2 Service Benchmarking
                           11.1.7.3 Financial Performance
                           11.1.7.4 Strategic Initiatives
                           11.1.7.5 Swot Analysis
                       11.1.8 ARISGLOBAL
                           11.1.8.1 Company Overview
                           11.1.8.2 Service Benchmarking
                           11.1.8.3 Financial Performance
                           11.1.81.4 Strategic Initiatives
                           11.1.8.5 Swot Analysis
                       11.1.9 ICON PLC.
                           11.1.9.1 Company Overview
                           11.1.9.2 Service Benchmarking
                           11.1.9.3 Financial Performance
                           11.1.9.4 Strategic Initiatives
                           11.1.9.5 Swot Analysis
                       11.1.10 CAPGEMINI
                           11.1.10.1 Company Overview
                           11.1.10.2 Service Benchmarking
                           11.1.10.3 Financial Performance
                           11.1.10.4 Strategic Initiatives
                           11.1.10.5 Swot Analysis
                       11.1.11 ITCLINICAL
                           11.1.11.1 Company Overview
                           11.1.11.2 Service Benchmarking
                           11.1.11.3 Financial Performance
                           11.1.11.4 Strategic Initiatives
                           11.1.11.5 Swot Analysis
                       11.1.12 BIOCLINICA, INC.
                           11.1.12.1 Company Overview
                           11.1.12.2 Service Benchmarking
                           11.1.12.3 Financial Performance
                           11.1.12.4 Strategic Initiatives
                           11.1.12.5 Swot Analysis
                       11.1.13 WIPRO
                           11.1.13.1 Company Overview
                           11.1.13.2 Service Benchmarking
                           11.1.13.3 Financial Performance
                           11.1.13.4 Strategic Initiatives
                           11.1.13.5 Swot Analysis
                       11.1.14 UNITED BIOSOURCE LLC
                           11.1.14.1 Company Overview
                           11.1.14.2 Service Benchmarking
                           11.1.14.3 Financial Performance
                           11.1.14.4 Strategic Initiatives
                           11.1.14.5 Swot Analysis
                       11.1.15 FMD K&L (CLINCHOICE)
                           11.1.15.1 Company Overview
                           11.1.15.2 Service Benchmarking
                           11.1.15.3 Financial Performance
                           11.1.15.4 Strategic Initiatives
                           11.1.15.5 Swot Analysis
Chapter 12 Winning Strategies
                  12.1 Key Winning/Scoring Criteria
                       12.1.1 By Categories
                           12.1.1.1 Pharmaceuticals
                           12.1.1.2 Biotech companies
                           12.1.1.3 Medical device companies
                  12.2 Key Vendor Selection Factors
                       12.2.1 By Category
                       12.2.2 By Company Size
                           12.2.2.1 Key Takeaways
Chapter 13 Switching Cost Analysis
Chapter 14 Research Methodology & Scope
                  14.1 Market Segmentation & Scope
                       14.1.1 Product Life Cycle
                       14.1.2 Service Provider
                       14.1.3 Type
                       14.1.4 Process Flow
                       14.1.5 Therapeutic Area
                       14.1.6 End Use
                       14.1.7 Regional Scope
                       14.1.8 Estimates And Forecast Timeline
                  14.2 Research Methodology
                  14.3 Information Procurement
                       14.3.1 Purchased Database:
                       14.3.2 GVR’S Internal Database
                       14.3.3 Secondary Sources
                       14.3.4 Primary Research:
                       14.3.5 Details Of Primary Research
                           14.3.5.1 Data for primary interviews in North America
                           14.3.5.2 Data for Primary Interviews in Europe
                           14.3.5.3 Data for Primary Interviews in APAC
                           14.3.5.4 Data for Primary Interviews in Latin America
                           14.3.5.5 Data for Primary Interviews in MEA
                  14.4 Information or Data Analysis
                       14.4.1 Data Analysis Models
                  14.5 Market Formulation & Validation
                  14.6 Model Details
                       14.6.1 Commodity Flow Analysis
                           14.6.1.1 Top-down market estimation
                           14.6.1.2 CAGR Calculation
                           14.6.1.3 Key Report Updates
                  14.7 List of Secondary Sources
                  14.8 List of Abbreviations
                  14.9 Market Definitions
                  14.10 Report Objectives
                       14.10.1 OBJECTIVE 1:
                       14.10.2 OBJECTIVE 2:
Chapter 15 Appendix

List of Tables

Table 1 List of secondary sources
Table 2 List of Abbreviation
Table 3 Types of ADRs
Table 4 Adverse Drug Events (ADEs) in hospitals
Table 5 List of regulations, by country
Table 6 Estimated Total Per-Study Costs (in $ Millions), by Phase and Therapeutic Area
Table 7 Case management costing by year
Table 8 Price by case processing volume
Table 9 Total literature searches (2013-2019)
Table 10 Outsourcing trend observed in pharmaceutical companies
Table 11 List of Major Deals & Acquisitions
Table 12 Europe Pharmacovigilance Market, by clinical phase, 2018 - 2030 (USD Million)
Table 13 Europe Pharmacovigilance Market, by service provider, 2018 - 2030 (USD Million)
Table 14 Europe Pharmacovigilance Market, by type, 2018 - 2030 (USD Million)
Table 15 Europe Pharmacovigilance Market, by end use, 2018 - 2030 (USD Million)
Table 16 Europe Pharmacovigilance Market, by process flow, 2018 - 2030 (USD Million)
Table 17 Europe Pharmacovigilance Market, by therapeutic area, 2018 - 2030 (USD Million)
Table 18 UK Pharmacovigilance Market, by clinical phase, 2018 - 2030 (USD Million)
Table 19 UK Pharmacovigilance Market, by service provider, 2018 - 2030 (USD Million)
Table 20 UK Pharmacovigilance Market, by type, 2018 - 2030 (USD Million)
Table 21 UK Pharmacovigilance Market, by end use, 2018 - 2030 (USD Million)
Table 22 UK Pharmacovigilance Market, by process flow, 2018 - 2030 (USD Million)
Table 23 UK Pharmacovigilance Market, by therapeutic area, 2018 - 2030 (USD Million)
Table 24 Germany Pharmacovigilance Market, by clinical phase, 2018 - 2030 (USD Million)
Table 25 Germany Pharmacovigilance Market, by service provider, 2018 - 2030 (USD Million)
Table 26 Germany Pharmacovigilance Market, by type, 2018 - 2030 (USD Million)
Table 27 Germany Pharmacovigilance Market, by end use, 2018 - 2030 (USD Million)
Table 28 Germany Pharmacovigilance Market, by process flow, 2018 - 2030 (USD Million)
Table 29 Germany Pharmacovigilance Market, by therapeutic area, 2018 - 2030 (USD Million)
Table 30 France Pharmacovigilance Market, by clinical phase, 2018 - 2030 (USD Million)
Table 31 France Pharmacovigilance Market, by service provider, 2018 - 2030 (USD Million)
Table 32 France Pharmacovigilance Market, by type, 2018 - 2030 (USD Million)
Table 33 France Pharmacovigilance Market, by end use, 2018 - 2030 (USD Million)
Table 34 France Pharmacovigilance Market, by process flow, 2018 - 2030 (USD Million)
Table 35 France Pharmacovigilance Market, by therapeutic area, 2018 - 2030 (USD Million)
Table 36 Italy Pharmacovigilance Market, by clinical phase, 2018 - 2030 (USD Million)
Table 37 Italy Pharmacovigilance Market, by service provider, 2018 - 2030 (USD Million)
Table 38 Italy Pharmacovigilance Market, by type, 2018 - 2030 (USD Million)
Table 39 Italy Pharmacovigilance Market, by end use, 2018 - 2030 (USD Million)
Table 40 Italy Pharmacovigilance Market, by process flow, 2018 - 2030 (USD Million)
Table 41 Italy Pharmacovigilance Market, by therapeutic area, 2018 - 2030 (USD Million)
Table 42 Spain Pharmacovigilance Market, by clinical phase, 2018 - 2030 (USD Million)
Table 43 Spain Pharmacovigilance Market, by service provider, 2018 - 2030 (USD Million)
Table 44 Spain Pharmacovigilance Market, by type, 2018 - 2030 (USD Million)
Table 45 Spain Pharmacovigilance Market, by end use, 2018 - 2030 (USD Million)
Table 46 Spain Pharmacovigilance Market, by process flow, 2018 - 2030 (USD Million)
Table 47 Spain Pharmacovigilance Market, by therapeutic area, 2018 - 2030 (USD Million)
Table 48 Sweden Pharmacovigilance Market, by clinical phase, 2018 - 2030 (USD Million)
Table 49 Sweden Pharmacovigilance Market, by service provider, 2018 - 2030 (USD Million)
Table 50 Sweden Pharmacovigilance Market, by type, 2018 - 2030 (USD Million)
Table 51 Sweden Pharmacovigilance Market, by end use, 2018 - 2030 (USD Million)
Table 52 Sweden Pharmacovigilance Market, by process flow, 2018 - 2030 (USD Million)
Table 53 Sweden Pharmacovigilance Market, by therapeutic area, 2018 - 2030 (USD Million)
Table 54 Denmark Pharmacovigilance Market, by clinical phase, 2018 - 2030 (USD Million)
Table 55 Denmark Pharmacovigilance Market, by service provider, 2018 - 2030 (USD Million)
Table 56 Denmark Pharmacovigilance Market, by type, 2018 - 2030 (USD Million)
Table 57 Denmark Pharmacovigilance Market, by end use, 2018 - 2030 (USD Million)
Table 58 Denmark Pharmacovigilance Market, by process flow, 2018 - 2030 (USD Million)
Table 59 Denmark Pharmacovigilance Market, by therapeutic area, 2018 - 2030 (USD Million)
Table 60 Norway Pharmacovigilance Market, by clinical phase, 2018 - 2030 (USD Million)
Table 61 Norway Pharmacovigilance Market, by service provider, 2018 - 2030 (USD Million)
Table 62 Norway Pharmacovigilance Market, by type, 2018 - 2030 (USD Million)
Table 63 Norway Pharmacovigilance Market, by end use, 2018 - 2030 (USD Million)
Table 64 Norway Pharmacovigilance Market, by process flow, 2018 - 2030 (USD Million)
Table 65 Norway Pharmacovigilance Market, by therapeutic area, 2018 - 2030 (USD Million)

List of Figures

Fig. 1 Pharmacovigilance market segmentation
Fig. 2 Market research process
Fig. 3 Data triangulation techniques
Fig. 4 Primary research pattern
Fig. 5 Primary interviews in North America
Fig. 6 Primary interviews in Europe
Fig. 7 Primary interviews in APAC
Fig. 8 Primary interviews in Latin America
Fig. 9 Primary interviews in MEA
Fig. 10 Market research approaches
Fig. 11 Value-chain-based sizing & forecasting
Fig. 12 QFD modeling for market share assessment
Fig. 13 Market formulation & validation
Fig. 14 Timeline of pharmacovigilance for a drug from development (premarket to post marketing)
Fig. 15 Market Snapshot
Fig. 16 Segment Snapshot (Product Life Cycle & Service Provider)
Fig. 17 Segment Snapshot (Type & Therapeutic Area)
Fig. 18 Segment Snapshot (Process Flow & End Use))
Fig. 19 Competitive Landscape Snapshot
Fig. 20 Penetration & growth prospect mapping
Fig. 21 Pharmacovigilance market dynamics
Fig. 22 Porter’s five force model
Fig. 23 Pharmacovigilance - SWOT analysis, by factor (political & legal, economic, and technological)
Fig. 24 Pharmacovigilance & Patient Safety Services - Product Life Cycle
Fig. 25 PV department
Fig. 26 PV organization structure
Fig. 27 Estimated budget allocation of drug safety activities at global and country-level
Fig. 28 Comparison between estimated global and country-level drug safety budget allocation
Fig. 29 Average % of drug safety budget contributed by function at a global level
Fig. 30 Pharmacovigilance system cost for small-sized firms and larger-sized firms
Fig. 31 Clinical trial cost by phase (%)
Fig. 32 Selected clinical trials costs based on technology
Fig. 33 Estimated cost of developing therapeutic medical device in the U.S.
Fig. 34 The average monthly cost of illness due to ADRs
Fig. 35 Medical Writers Employers by Industry
Fig. 36 Trending topics on social media (2017)
Fig. 37 ADR detection and from social media data
Fig. 38 Common literature automation tool flow
Fig. 39 Automation processes in PV
Fig. 40 Deterrents to Leveraging the Cloud (Oracle Survey)
Fig. 41 The three-step process to compute signal statistics from search log using big data
Fig. 42 Risk Management Capacity &Capability with Pharmacovigilance Using Big Data
Fig. 43 Pharma & Biotech R&D expense growth, 2020 (%)
Fig. 44 Medical writing market outlook, 2022 (USD Million)
Fig. 45 Medical writing market, 2018 - 2030 (USD Million)
Fig. 46 Europe medical safety review market, 2018 - 2030 (USD Million)
Fig. 47 Europe Pharmacovigilance market: Product life cycle movement analysis
Fig. 48 Europe Pharmacovigilance market product life cycle dashboard
Fig. 49 Europe Preclinical market, 2018 - 2030 (USD MILLION)
Fig. 50 Europe Phase I market, 2018 - 2030 (USD MILLION)
Fig. 51 Europe Phase II market, 2018 - 2030 (USD MILLION)
Fig. 52 Europe Phase III market, 2018 - 2030 (USD MILLION)
Fig. 53 Adverse events reported in FAERS system, 2019-2022
Fig. 54 Europe Phase IV market, 2018 - 2030 (USD MILLION)
Fig. 55 Europe Pharmacovigilance market: Service provider movement analysis
Fig. 56 Europe Pharmacovigilance Service provider dashboard
Fig. 57 Europe In-house market, 2018 - 2030 (USD MILLION)
Fig. 58 Europe contract outsourcing market, 2018 - 2030 (USD MILLION)
Fig. 59 Europe Pharmacovigilance market: Type movement analysis
Fig. 60 Europe Pharmacovigilance type dashboard
Fig. 61 Europe spontaneous reporting market, 2018 - 2030 (USD MILLION)
Fig. 62 Europe intensified ADR reporting market, 2018 - 2030 (USD MILLION)
Fig. 63 Europe targeted spontaneous reporting market, 2018 - 2030 (USD MILLION)
Fig. 64 Europe CEM market, 2018 - 2030 (USD MILLION)
Fig. 65 Europe EHR mining market, 2018 - 2030 (USD MILLION)
Fig. 66 Europe Pharmacovigilance market: Process flow movement analysis
Fig. 67 Europe Pharmacovigilance market process flow dashboard
Fig. 68 Europe case data management market, 2018 - 2030 (USD MILLION)
Fig. 69 Europe case logging market, 2018 - 2030 (USD MILLION)
Fig. 70 Europe case data analysis market, 2018 - 2030 (USD MILLION)
Fig. 71 Europe medical reviewing and reporting market, 2018 - 2030 (USD MILLION)
Fig. 72 Europe signal detection market, 2018 - 2030(USD Million)
Fig. 73 Europe adverse event logging market, 2018 - 2030 (USD MILLION)
Fig. 74 Europe adverse event analysis market, 2018 - 2030 (USD MILLION)
Fig. 75 Europe adverse event review & reporting market, 2018 - 2030 (USD MILLION)
Fig. 76 Europe risk management system market, 2018 - 2030 (USD MILLION)
Fig. 77 Europe Risk Evaluation System market, 2018 - 2030 (USD MILLION)
Fig. 78 Europe risk mitigation system market, 2018 - 2030 (USD MILLION)
Fig. 79 Europe Pharmacovigilance market: Therapeutic area movement analysis
Fig. 80 Europe Pharmacovigilance market therapeutic area dashboard
Fig. 81 Europe oncology market, 2018 - 2030 (USD MILLION)
Fig. 82 Europe neurology market, 2018 - 2030 (USD MILLION)
Fig. 83 Europe cardiology market, 2018 - 2030 (USD MILLION)
Fig. 84 Europe respiratory systems market, 2018 - 2030 (USD MILLION)
Fig. 85 Europe others market, 2018 - 2030 (USD MILLION)
Fig. 86 Europe Pharmacovigilance market: End use movement analysis
Fig. 87 Europe Pharmacovigilance market end use dashboard
Fig. 88 Europe pharmaceuticals market, 2018 - 2030 (USD MILLION)
Fig. 89 Europe biotechnology companies’ market, 2018 - 2030 (USD MILLION)
Fig. 90 Europe medical device manufacturers market, 2018 - 2030 (USD MILLION)
Fig. 91 Europe others market, 2018 - 2030 (USD MILLION)
Fig. 92 Country market place: Key takeaways
Fig. 93 UK key country dynamics (Part 1)
Fig. 94 UK key country dynamics (Part 2)
Fig. 95 UK pharmacovigilance market, 2018 - 2030 (USD Million)
Fig. 96 Germany key country dynamics (Part 1)
Fig. 97 Germany key country dynamics (Part 2)
Fig. 98 Germany pharmacovigilance market, 2018 - 2030 (USD Million)
Fig. 99 France key country dynamics (Part 1)
Fig. 100 France key country dynamics (Part 2)
Fig. 101 France pharmacovigilance market, 2018 - 2030 (USD Million)
Fig. 102 Italy key country dynamics (Part 1)
Fig. 103 Italy key country dynamics (Part 2)
Fig. 104 Italy pharmacovigilance market, 2018 - 2030 (USD Million)
Fig. 105 Spain key country dynamics (Part 1)
Fig. 106 Spain key country dynamics (Part 2)
Fig. 107 Spain pharmacovigilance market, 2018 - 2030 (USD Million)
Fig. 108 Russia key country dynamics
Fig. 109 Russia pharmacovigilance market, 2018 - 2030 (USD Million)
Fig. 110 Denmark key country dynamics (Part 1)
Fig. 111 Denmark key country dynamics (Part 2)
Fig. 112 Denmark pharmacovigilance market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 113 Norway key country dynamics (Part 1)
Fig. 114 Norway key country dynamics (Part 2)
Fig. 115 Norway pharmacovigilance market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 116 Sweden key country dynamics (Part 1)
Fig. 117 Sweden key country dynamics (Part 2)
Fig. 118 Sweden pharmacovigilance market estimates and forecasts, 2018 - 2030 (USD Million)